Molecular Mammography of Her-2 Cancers using Gold Nanoparticles

描述(申请人提供)：癌症成像对于肿瘤检测、决定预后和治疗、影像引导手术和放射治疗以及监测反应都很重要。特定靶点的分子成像可以识别肿瘤类型，并能够选择合适的药物。虽然与PET、SPECT和MRI相比，X射线成像应用广泛、速度更快、分辨率更高，但目前还没有靶向的X射线造影剂。在这项提议中，我们将利用金纳米粒子对癌症进行成像，通过纳米技术方法开发用于乳房X光检查的分子靶向试剂。乳腺癌细胞上的HER-2蛋白将通过使用附着在生物相容的金纳米颗粒上的抗体来靶向，使用小鼠模型。这将有助于对这种突变的体内非侵入性检测，这种突变发生在大约30%的人类乳腺癌中，然后可以用单抗Herceptin(R)进行有益的治疗。分子乳房X光成像将改进痛苦的活检所提供的有限样本，并提供更彻底的检测，即使是细小的肿瘤和活检和其他方法遗漏的转移。这将使人们能够更早地发现乳腺癌。更好的肿瘤清晰度也将改善精确的放射治疗、手术和后续监测。如果成功，这项技术可以应用于其他肿瘤的早期检测和生化分型，以实现更有效的个体化治疗。对公众健康：将开发一种使用纳米技术的新方法，以改进非侵入性成像和通过乳房X光照相检测乳腺癌类型。这不仅能够更好地及早发现较小的肿瘤和转移，而不需要痛苦的活检，而且还应该识别肿瘤类型，以便能够对这种类型的特定药物进行管理。存在检测Her2乳腺癌的需要，Her2乳腺癌约占乳腺癌的30%，在这种情况下可以获得特定的药物Herceptin(R)并提高存活率。

DESCRIPTION (provided by applicant): Cancer imaging is important for tumor detection, determination of prognosis and treatments, image guided surgery and irradiation, as well as for monitoring responses. Molecular imaging of specific targets could identify tumor types and enable selection of appropriate drugs. Although x-ray imaging is widely used and more rapid with higher resolution compared to PET, SPECT, and MRI, there are currently no targeted x-ray contrast agents. In this proposal we will develop molecular targeted agents for mammography by a nanotechnology approach using gold nanoparticles for imaging cancers. The Her 2 protein on breast cancer cells will be targeted by use of antibodies attached to biocompatible gold nanoparticles using a mouse model. This would then be useful for non-invasive in vivo detection of this mutation which occurs in about 30% of human breast cancers that could then be beneficially treated with the monoclonal antibody Herceptin(r). Molecular mammography imaging would improve on the limited sampling afforded by painful biopsies and provide more thorough detection of even small tumors and metastases missed by biopsies and other methods. It would enable earlier detection of breast cancer. Better tumor definition would also improve precise radiotherapy, surgery, and follow-up monitoring. If successful, this technology could be applied to other tumors for early detection and biochemical typing for more effective individualized treatments. To Public Health: A novel method using nanotechnology will be developed for improved non-invasive imaging and detection of breast cancer types by mammography. This should not only enable better early detection of smaller tumors and metastases without painful biopsies, but identify tumor types so that specific drugs for the type can be administered. Such a need exists to detect Her2 breast cancers, which account for about 30% of breast cancers, where the specific drug Herceptin(r) is available and improves survival.